|
|
|
|
|
by outworlder
1224 days ago
|
|
> Newer versions of insulin are "better" than generic insulin: easier to take, fewer side effects, etc. Even that is debatable. At least Sanofi has been known to fund some rosy articles about their Lantus® product. When the EU looked into it (for similar initiatives) they were not able to find the large 'performance' gap that was suggested between that insulin and alternatives. |
|
I suppose off-patent insulin could be produced with some degree of inconvenience to the consumer because they might have to take more doses per day, but they should work nonetheless.